iRhythm Technologies (Nasdaq:IRTC) this week announced it appointed Dr. Mintu Turakhia as chief medical officer and chief scientific officer.
Turakhia is a professor of medicine at the Stanford University School of Medicine and the director and co-founder of the Stanford Center for Digital Health. He is also a cardiac electrophysiologist with more than 20 years of experience in patient care, outcomes research and trials, data science and artificial intelligence, medical device regulation, and the creation and commercialization of digital health products.
According to the company, Turakhia performed the first study of silent atrial fibrillation with iRhythm’s original Zio patch, which helped the company perform large atrial fibrillation studies at scale.
“As healthcare continues to evolve at a rapid pace, we are very excited to add Dr. Turakhia to our executive team,” CEO Quentin Blackford said in a news release. “Mintu is a prolific scientist, respected clinician, and fast thinker whose work in heart rhythm and digital health is on the leading edge of healthcare innovation. Mintu’s forward-thinking approach to the future of medicine, including advanced technologies, artificial intelligence, and new models of care delivery will help iRhythm continue its evolution as a market leader in the digital healthcare space.”
Chief clinical officer Judy Lenane also announced her retirement after 14 years with the company.
“We would like to thank Judy for her significant contributions to iRhythm during her tenure. Her clinical, medical and strategic expertise has been crucial to getting our company to where we are today, and her unwavering patient focus will have an enduring influence on our company,” Blackford said.